

## **Serina Therapeutics Announces Advancing to Multi-Dose Phase in Parkinson's Disease Patients in the SER-214 Phase I Trial**

Huntsville, AL, June 6<sup>th</sup>, 2016

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has advanced to the multi-dose phase of the trial investigating the safety, tolerability and pharmacokinetics of SER-214 in Parkinson's disease.

"We are delighted to announce that the multi-dose phase of the SER-214 Phase I clinical trial has begun," stated Randall Moreadith, MD, PhD, President and CEO of Serina Therapeutics. "SER-214 is a once-per-week subcutaneous injection that can be delivered in a standard insulin syringe. This approach may offer Parkinson's disease patients an alternative to existing therapies that do not provide steady-state blood concentrations. The results from the single-dose phase show that SER-214 is safe, well-tolerated and has predictable pharmacokinetics. We are on track to complete the Phase I trial around the end of 2016."

SER-214 is Serina's most advanced wholly-owned polymer conjugate. SER-214 is a once-per-week injectable that is chemically programmed to result in continuous drug delivery. Continuous dopaminergic stimulation, which would result from continuous drug delivery, has been a long-sought clinical strategy to ameliorate the sometimes disabling consequences of oral treatment with short-acting L-DOPA formulations and dopamine agonists. Information on the SER-214 Phase I trial can be found on ClinicalTrials.gov at the following link: <https://clinicaltrials.gov/show/NCT02579473>.

Serina's pipeline programs are aimed primarily at CNS and oncology indications that address significant unmet medical needs. In the last three years Serina has executed partnerships with two of the top ten pharmaceutical companies worldwide to employ POZ<sup>TM</sup> technology. POZ polymers can deliver small molecule therapeutics (as in SER-214) or can be targeted to specific receptors on the surface of cancer cells using either small molecules or antibodies as targeting moieties. This latter approach may provide a wider therapeutic index when employing very potent toxins attached to the polymer, and when targeting low-density receptors on the surface of cancer cells.

### **About Serina**

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL. Serina develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ<sup>TM</sup>) technology. The founders and executives of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. In addition to developing its own pipeline of pharmaceutical products for Parkinson's disease, cancer and post-operative pain, Serina is actively seeking partners for its technology to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit <http://www.serinatherapeutics.com>